

Joel D Kallich

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/4797156/publications.pdf>

Version: 2024-02-01

42
papers

2,530
citations

331670

21
h-index

315739

38
g-index

43
all docs

43
docs citations

43
times ranked

3287
citing authors

#	ARTICLE	IF	CITATIONS
1	Development of the Kidney Disease Quality of Life (KDQOLTM) Instrument. <i>Quality of Life Research</i> , 1994, 3, 329-338.	3.1	946
2	Health Care Costs for Patients With Cancer at the End of Life. <i>Journal of Oncology Practice</i> , 2012, 8, 75s-80s.	2.5	206
3	The longitudinal relationship of hemoglobin, fatigue and quality of life in anemic cancer patients: results from five randomized clinical trials. <i>Annals of Oncology</i> , 2004, 15, 979-986.	1.2	201
4	Patient-Reported Outcomes: Instrument Development and Selection Issues. <i>Value in Health</i> , 2007, 10, S86-S93.	0.3	122
5	A review of health-related quality-of-life measures used in end-stage renal disease. <i>Clinical Therapeutics</i> , 1996, 18, 887-938.	2.5	111
6	Platelet transfusions: Utilization and associated costs in a tertiary care hospital. <i>American Journal of Hematology</i> , 2000, 64, 251-256.	4.1	91
7	An Evaluation of Algorithms for Identifying Metastatic Breast, Lung, or Colorectal Cancer in Administrative Claims Data. <i>Medical Care</i> , 2015, 53, e49-e57.	2.4	84
8	The relationship between psychologic distress and cancer-related fatigue. <i>Cancer</i> , 2003, 98, 198-203.	4.1	71
9	Identification of metastatic cancer in claims data. <i>Pharmacoepidemiology and Drug Safety</i> , 2012, 21, 21-28.	1.9	71
10	Dissemination of effectiveness and outcomes research. <i>Health Policy</i> , 1995, 34, 167-192.	3.0	65
11	The Economic Burden of Anemia in Cancer Patients Receiving Chemotherapy. <i>Value in Health</i> , 2005, 8, 149-156.	0.3	61
12	Medication adherence and fracture risk among patients on bisphosphonate therapy in a large United States health plan. <i>Bone</i> , 2012, 50, 870-875.	2.9	57
13	Development of subscales from the symptoms/problems and effects of kidney disease scales of the kidney disease quality of life instrument. <i>Clinical Therapeutics</i> , 2000, 22, 1099-1111.	2.5	39
14	Efficacy of Darbepoetin Alfa in Alleviating Fatigue and the Effect of Fatigue on Quality of Life in Anemic Patients with Lymphoproliferative Malignancies. <i>Journal of Pain and Symptom Management</i> , 2006, 31, 317-325.	1.2	38
15	Cost burden of second fracture in the US Health System. <i>Bone</i> , 2011, 48, 828-836.	2.9	37
16	Osteoporosis medication adherence: Physician perceptions vs. patients' utilization. <i>Bone</i> , 2013, 55, 1-6.	2.9	37
17	Disruptions in Rheumatology Care and the Rise of Telehealth in Response to the COVID-19 Pandemic in a Community Practice-Based Network. <i>Arthritis Care and Research</i> , 2021, 73, 1153-1161.	3.4	32
18	Reductions in Anaemia and Fatigue are Associated with Improvements in Productivity in Cancer Patients Receiving Chemotherapy. <i>Pharmacoeconomics</i> , 2005, 23, 505-514.	3.3	31

#	ARTICLE	IF	CITATIONS
19	Direct Healthcare Costs of Osteoporosis-Related Fractures in Managed Care Patients Receiving Pharmacological Osteoporosis Therapy. <i>Applied Health Economics and Health Policy</i> , 2012, 10, 163-173.	2.1	28
20	The Impact of Anaemia and its Treatment on Employee Disability and Medical Costs. <i>Pharmacoeconomics</i> , 2005, 23, 183-192.	3.3	25
21	Psychological outcomes associated with anemia-related fatigue in cancer patients. <i>Oncology</i> , 2002, 16, 117-24.	0.5	21
22	The Impact of Methodological Approach on Cost Findings in Comparison of Epoetin Alfa with Darbepoetin Alfa. <i>Annals of Pharmacotherapy</i> , 2009, 43, 1203-1210.	1.9	18
23	The Importance of Clinical Variables in Comparative Analyses Using Propensity-Score Matching. <i>Pharmacoeconomics</i> , 2009, 27, 755-765.	3.3	17
24	Development of a fatigue and functional impact scale in anemic cancer patients receiving chemotherapy. <i>Cancer</i> , 2008, 113, 1480-1488.	4.1	16
25	Resource Utilisation and Time Commitment Associated with Correction of Anaemia in Cancer Patients Using Epoetin Alfa. <i>Clinical Drug Investigation</i> , 2006, 26, 593-601.	2.2	13
26	Costs Associated with Erythropoiesis-Stimulating Agent Administration to Hemodialysis Patients. <i>Nephron Clinical Practice</i> , 2007, 106, c193-c198.	2.3	13
27	The Relationship Between Patient Knowledge of Hemoglobin Levels and Health-Related Quality of Life. <i>Quality of Life Research</i> , 2006, 15, 57-68.	3.1	12
28	Patient and caregiver time burden associated with anaemia treatment in different patient populations. <i>Supportive Care in Cancer</i> , 2006, 14, 1195-1204.	2.2	12
29	Use of darbepoetin alfa and epoetin alfa in clinical practice in patients with cancer-related anemia. <i>Clinical Therapeutics</i> , 2008, 30, 206-218.	2.5	10
30	Patterns of osteoporosis treatment change and treatment discontinuation among commercial and Medicare Advantage Prescription Drug members in a national health plan. <i>Journal of Evaluation in Clinical Practice</i> , 2013, 19, 50-59.	1.8	8
31	Using Certification to Promote Uptake of Real-World Evidence by Payers. <i>Journal of Managed Care & Specialty Pharmacy</i> , 2016, 22, 191-196.	0.9	8
32	Problems with analyses and interpretation of data in use of the KDQOL-36 for assessment of health-related quality of life among dialysis patients in the United States. <i>BMC Nephrology</i> , 2019, 20, 447.	1.8	7
33	Hemoglobin Increase Is Associated with Improved Health-Related Quality of Life in Patients with Cancer Not Receiving Chemotherapy. <i>Supportive Cancer Therapy</i> , 2003, 1, 49-54.	0.3	5
34	Budget impact analysis of darbepoetin alfa every 3 weeks versus epoetin alfa every week for the treatment of chemotherapy-induced anaemia from a US payer's perspective. <i>Journal of Medical Economics</i> , 2008, 11, 199-213.	2.1	5
35	Use and cost of erythropoiesis-stimulating agents in patients with cancer. <i>Current Medical Research and Opinion</i> , 2009, 25, 1775-1784.	1.9	5
36	Association between osteoporosis treatment change and adherence, incident fracture, and total healthcare costs in a Medicare Advantage Prescription Drug plan. <i>Osteoporosis International</i> , 2013, 24, 1195-1206.	3.1	3

#	ARTICLE	IF	CITATIONS
37	Performance status of real-world oncology patients before and after first course of chemotherapy. Journal of Community and Supportive Oncology, 2014, 12, 163-170.	0.1	3
38	Patterns of Care in Patients with Chemotherapy Receiving Erythropoiesis Stimulating Agents (ESAs).. Blood, 2007, 110, 964-964.	1.4	1
39	Comment: The Impact of Methodological Approach on Cost Findings in Comparison of Epoetin Alfa with Darbepoetin Alfa. Annals of Pharmacotherapy, 2010, 44, 595-596.	1.9	0
40	Impact of Clinical/Demographic Characteristics and Duration of Clinical Benefit on Average Weekly Doses of Darbepoetin Alfa and Epoetin Alfa in Oncology: Results from a Claims Analysis.. Blood, 2006, 108, 5538-5538.	1.4	0
41	The Importance of Clinical Variables for Propensity Score Matching When Comparing Costs: The Case of ESA Treatments for Chemotherapy Induced Anemia. Blood, 2008, 112, 4695-4695.	1.4	0
42	The Impact of Methodological Approach on Cost Findings in Comparison of Epoetin Alfa with Darbepoetin Alfa. Blood, 2008, 112, 1298-1298.	1.4	0